Latest News
Centers for Medicare and Medicaid Services Publishes Draft Coverage Decision to Reimburse the Decipher® Test for Intermediate & High Risk Prostate Cancer
GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical prostatectomy. An LCD is a decision by Medicare contractors to cover an item or service. Decipher is the only genomic test for prostate cancer to receive a draft LCD for use in the post-surgery setting…Read More